Following the company’s most recent quarterly results, Clarus Securities analyst Noel Atkinson has cut his target on HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:HLS) nearly in half. On March 16, HLS reported its Q4 and fiscal 2022 results. For the year, the company posted a net loss of $23.6-million on revenue […]
Biotech, more than any other sector, is a game of longshots. Most great investors in the space own a basket of ten or more stocks. They’re not looking for a tidy ten per cent gain, they’re looking for a life-changing fifty bagger. So how do you find great candidates? Look no further, by following us […]
Share
Tweet
Share
